TPST — Tempest Therapeutics Share News
0.000.00%
Last trade - 00:00Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study
Brief: Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Brief: Tempest Appoints Sheldon Mullins As Vice President, Regulatory Affairs
U.S. STOCKS ON THE MOVE-Boeing, AST SpaceMobile, Syndax
Tempest rises on positive FDA feedback for cancer therapy study
Tempest Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Tempest Therapeutics- Planning To Move Tpst-1495 Into A Phase 2 In Fap
Tempest Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: Tempest Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: Tempest Therapeutics Terminated Prior Sales Agreement And Entered New Open Market Sale Agreement
Brief: Tempest Therapeutics Amezalpat Data In Randomized First-Line HCC Study Shows 6-Month Improvement Versus Control Arm
Tempest Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Tempest Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Tempest Therapeutics Says Ended Year With $39.2 Million In Cash And Cash Equivalents